- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
FDA Approves Biocon Biologics' Bevacizumab Biosimilar
Biocon Biologics expands its oncology biosimilar roster after gaining FDA approval for Jobevne (bevacizumab-nwgd), the sixth biosimilar referencing Avastin (bevacizumab).
The present approval adds to the company’s growing oncology portfolio in the US, which already includes Ogivri (trastuzumab-dkst) for HER2-positive breast cancer and Fulphila (pegfilgrastim-jmdb) to reduce the risk of febrile neutropenia in patients undergoing chemotherapy. | Image Credit: gguy - stock.adobe.com .jpeg
Biocon Biologics expands its oncology biosimilar roster after gaining FDA approval for Jobevne (bevacizumab-nwgd), the sixth biosimilar referencing Avastin (bevacizumab).1,2
The new recombinant humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF) receptors is indicated for the treatment of colorectal cancer, non–small cell lung cancer, glioblastoma, renal cell carcinoma, and cervical cancer, ovarian, fallopian tube, and primary peritoneal cancers.1
"The U.S\ FDA approval of Jobevne (bevacizumab-nwgd) is a significant milestone—our seventh biosimilar approved in the US and a strong addition to our robust oncology portfolio. It underscores the depth of our scientific expertise and commitment to expanding access to high-quality, affordable biologics. We look forward to working with all stakeholders to bring more treatment options to patients," commented Shreehas Tambe, CEO and managing director, Biocon Biologics, in a statement.
In addition to cancer indications, reference bevacizumab (Avastin) is often used off label for age-related macular degeneration, diabetic macular edema, retinal vein occlusions, neovascular glaucoma, corneal vascularization, pterygium, and after trabeculectomy to prevent bleb failure.3 Biosimilars could provide greater access to biosimilar therapies for these conditions as well.
Jobevne joins 5 other Avastin competitors: Celltrion's Vegzelma (bevacizumab-adcd), Amgen/Allergan's Mvasi (bevacizumab-awwb), Pfizer's Zirabev (bevacizumab-bvzr), Amneal Pharmaceuticals/Kashiv Biosciences Alymsys (bevacizumab-maly), and Sandoz/Bio-Thera Solutions' Avzivi (bevacizumab-tnjn).2
The present approval adds to the company’s growing oncology portfolio in the US, which already includes Ogivri (trastuzumab-dkst) for HER2-positive breast cancer and Fulphila (pegfilgrastim-jmdb) to reduce the risk of febrile neutropenia in patients undergoing chemotherapy.1 The biosimilar has also been approved in Europe and Canada, where it's marketed under the brand name Abevmy.2
In addition to its oncology biosimilars, the company has made significant strides in diabetes care with the launch of Semglee (insulin glargine-yfgn), the first interchangeable biosimilar approved in the US.4 With products in over 120 countries and a pipeline packed with 20 biosimilars in development across different therapeutic areas, the company said it is keeping its focus on making high-quality biologics more accessible and affordable for people around the world.
References
1. Biocon Biologics announces U.S. FDA approval for Jobevne, biosimilar bevacizumab, expanding Its oncology portfolio. Press release. Biocon Biologics; April 10, 2025. Accessed April 10, 2025. https://www.biocon.com/biocon-biologics-announces-u-s-fda-approval-for-jobevne-biosimilar-bevacizumab-expanding-its-oncology-portfolio/
2. Biosimilar approvals. The Center for Biosimilars®. Updated April 10, 2025. Accessed April 10, 2025. https://www.centerforbiosimilars.com/biosimilar-approvals
3. Singh S, Saxena S, Akduman L, Meyer CH. Off-label use of intravitreal bevacizumab: a global conundrum. Indian J Ophthalmol. 2024;72(5):617-619. doi:10.4103/IJO.IJO_2166_23
4. Hagen T. FDA approves Semglee insulin glargine as first interchangeable biosimilar. The Center for Biosimilars. July 28, 2021. Accessed April 10, 2025. https://www.centerforbiosimilars.com/view/fda-approves-semglee-insulin-glargine-as-first-interchangeable-biosimilar
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Risk-Adjusted NPV Framework for Biosimilars Shows Key Investment Drivers
April 7th 2025Early market entry, manufacturing efficiency, and market share are critical to biosimilar development success, while technical complexity and competition heavily impact returns, according to a study presenting a risk-adjusted net present value (NPV) analysis framework.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
FDA Approves Another Pair of Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The FDA approved another set of denosumab biosimilars, Conexxence/Bomyntra (denosumab-bnht), expanding treatment options for osteoporosis, bone metastases, and other bone-related conditions, amidst a flurry of similar approvals and legal settlements.
